UW Comprehensive Cancer Center Support

描述(由申请人提供)：威斯康星大学碳骨癌中心(UWCCC)由来自威斯康星大学麦迪逊分校45个系和11个学院的216名研究人员组成。威斯康星大学麦迪逊分校在基础、转化和临床癌症研究方面作为国际领先企业有着悠久而丰富的历史，这一点从哈罗德·拉什博士在威斯康星大学麦迪逊分校创建的两个由NCI指定并资助的癌症研究中心的历史中可见一斑。McArdle癌症研究实验室成立于1940年，并于1946年获得了NCI的最初资助。UWCCC自1973年作为首批六个综合性癌症中心之一获得NCI资助以来，一直获得NCI资助。经过20世纪90年代末S的协调进程，2001年，代表合并后的中心的第一笔国家癌症中心支持补助金颁发给了世界妇联癌症控制中心。这两个中心的合并在过去十年里为威斯康星大学麦迪逊分校的癌症研究带来了巨大的热情和增长。这导致中心大于合并前存在的两个部分的总和。随着威斯康星州医学研究院(WIMR)1号楼于2008年竣工，2号楼预计将于2013年完工，威斯康星州医学研究中心将拥有约350,000平方英尺的连续空间，专门用于癌症临床护理和研究，在过去十年中增加了近三倍。此外，新的威斯康星州发现研究所(WID)于2011年开业，这是一个耗资2亿美元的威斯康星大学麦迪逊分校中央校园研究设施，其中还包括私人运营的莫格里奇研究所(MIR)。WID/MIR将容纳10个专注的研究团队，每个团队有4名或更多的教职员工。其中五个团队由UWCCC成员领导，代表着WID/MIR中强大的癌症研究存在。WID四分之三的教职员工将是威斯康星大学麦迪逊分校的新员工。UWCCC未来的三个最高目标与目前的目标保持不变：1)对癌症的起源和控制进行最高质量的研究；2)通过尽可能具有相应生物终点的精心设计的临床试验，将这些研究结果转化为临床评估；以及3)以同情心和个性化的方式仔细地将高质量的尖端护理与临床研究相结合，为所有癌症患者提供尽可能最佳的护理。UWCCC有3070万美元的NCI资金(直接)和总计8370万美元的癌症重点研究资金。

DESCRIPTION (provided by applicant): The University of Wisconsin Carbone Cancer Center (UWCCC) is comprised of 216 research members from 45 departments and 11 schools of the University of Wisconsin Madison. UW-Madison has a long and rich history as an international leader in basic, translational and clinical cancer research reflected in its history of two NCI-designated and -funded cancer research centers founded by Dr. Harold Rusch on the UW-Madison campus. The McArdle Laboratory for Cancer Research was founded in 1940 and received its initial NCI funding in 1946. UWCCC has received continuous NCI funding since 1973 when it was awarded NCI funding as one of the first six comprehensive cancer centers. After a coordinated process during the late 1990's, both centers were consolidated under UWCCC in 2001 when the first NCI Cancer Center Support Grant representing the consolidated centers was awarded. The consolidation of the two centers has generated tremendous enthusiasm and growth for cancer research on the UW-Madison campus over the past ten years. This has resulted in a Center greater than the sum of the two parts existing before the consolidation. With the completion of the Wisconsin Institutes of Medical Research (WIMR) Tower 1 in 2008 and with Tower 2 completion projected for 2013, UWCCC will have approximately 350,000 sq ft of contiguous space dedicated to cancer clinical care and research, a nearly three-fold increase over the past ten years. In addition, the new Wisconsin Institutes of Discovery (WID), a $200 million UW-Madison central campus research facility that also includes the privately-operated Morgridge Institute for Research (MIR), opened in 2011. WID/MIR will house 10 focused research teams of four or more faculty each. Five of these teams are led by UWCCC members representing a strong cancer research presence in the WID/MIR. Three quarters of the faculty in WID will be new recruits to UW-Madison. The three future highest goals of UWCCC are unchanged from the current goals: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well-designed clinical trials with corresponding biologic endpoint whenever possible; and 3) to provide the best care possible to all cancer patients by carefully integrating high quality, cutting-edge care with clinical research in a compassionate and individualized manner. UWCCC has $30.7 million in NCI funding (direct) and a total of $83.7 million cancer focused research funding.